Opening “Pandora’s Box”: Witnesses Galore

• The drug prices have doubled and taxpayer harm has tripled since the initial Whistleblower case was filed in January 2014
  • $175+ billion over the past decade-plus (and rising every day) just for the 22 major U.S brand drugs in the Whistleblower cases

Witnesses Galore

• • Lots of “industry insiders” can quickly verify the straightforward, centralized “pharma fee” scheme
  • Pharma and health insurer/PBM senior executives
    • Many provided in the Whistleblower Court documents, but not pursued by DOJ

• • Industry legal and consultant advisers
    • Many provided in the Whistleblower Court documents, but not pursued by DOJ

• • Many other healthcare experts closely affiliated with the pharma and health insurance/PBM industries

THE DEPARTMENT OF JUSTICE (DOJ) REPEATEDLY ADMITTED NOT PURSUING THE 40-45 FIRSTHAND INSIDERS PROVIDED IN THE WHISTLEBLOWER LEGAL DOCUMENTS FROM THE ONE-OF-KIND OCTOBER 2013 “PHARMA FEE” CONFERENCE

• These first-hand insider witnesses, including numerous from the defendant companies, were the main reason the initial Whistbleblower case was filed in January 2014 with DOJ's encouragement
• Link to list of firsthand insider witnesses, from the Oct 2013 "pharma fee" conference, provided to the Government in the Whistleblower Complaints

DOJ REPEATEDLY ADMITTED INTERVIEWING ONLY ONE WITNESS (AN UNNAMED PBM EXECUTIVE) UNDER OATH DURING THE GOVERNMENT'S 4+ YEAR WHISTLEBLOWER INVESTIGATION

DOJ REPEATEDLY ADMITTED THAT NOT A SINGLE PHARMACEUTICAL EXECUTIVE WAS INTERVIEWED UNDER OATH DURING THE GOVERNMENT'S 4+ YEAR WHISTLEBLOWER INVESTIGATION

• Link to John R. Borzilleri, M.D.'s Affidavit filed with the Courts regarding his concerning firsthand feedback from DOJ during the Whistleblower investigation